{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:29:21Z","timestamp":1787020161943,"version":"build-2736575974"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,17]]},"DOI":"10.7759\/cureus.114690","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:28:52Z","timestamp":1787016532000},"source":"Crossref","is-referenced-by-count":0,"title":["A Case of Inadvertent Overdose of Vosoritide Injection in a Three-Month-Old Infant With Achondroplasia"],"prefix":"10.7759","author":[{"given":"Shunya","family":"Satake","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichiro","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(94)90302-6","article-title":"Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia","volume":"78","author":"Shiang R","year":"1994","unstructured":"Shiang R, Thompson LM, Zhu YZ, et al.. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell. 1994, 78:335-42. 10.1016\/0092-8674(94)90302-6","journal-title":"Cell"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813446","article-title":"C-type natriuretic peptide analogue therapy in children with achondroplasia","volume":"381","author":"Savarirayan R","year":"2019","unstructured":"Savarirayan R, Irving M, Bacino CA, et al.. C-type natriuretic peptide analogue therapy in children with achondroplasia. N Engl J Med. 2019, 381:25-35. 10.1056\/NEJMoa1813446","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-024-01074-9","article-title":"International consensus guidelines on the implementation and monitoring of vosoritide therapy in individuals with achondroplasia","volume":"21","author":"Savarirayan R","year":"2025","unstructured":"Savarirayan R, Hoover-Fong J, Ozono K, et al.. International consensus guidelines on the implementation and monitoring of vosoritide therapy in individuals with achondroplasia. Nat Rev Endocrinol. 2025, 21:314-24. 10.1038\/s41574-024-01074-9","journal-title":"Nat Rev Endocrinol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.59695","article-title":"Two cases of cardiovascular adverse events following subcutaneous vosoritide injection in early infancy","volume":"16","author":"Nishioka A","year":"2024","unstructured":"Nishioka A, Adachi N, Tanaka H, Oda Y. Two cases of cardiovascular adverse events following subcutaneous vosoritide injection in early infancy. Cureus. 2024, 16:e59695. 10.7759\/cureus.59695","journal-title":"Cureus"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-021-01059-1","article-title":"Pharmacokinetics and exposure-response of vosoritide in children with achondroplasia","volume":"61","author":"Chan ML","year":"2022","unstructured":"Chan ML, Qi Y, Larimore K, et al.. Pharmacokinetics and exposure-response of vosoritide in children with achondroplasia. Clin Pharmacokinet. 2022, 61:263-80. 10.1007\/s40262-021-01059-1","journal-title":"Clin Pharmacokinet"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(23)00265-1","article-title":"Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"8","author":"Savarirayan R","year":"2024","unstructured":"Savarirayan R, Wilcox WR, Harmatz P, et al.. Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Child Adolesc Health. 2024, 8:40-50. 10.1016\/S2352-4642(23)00265-1","journal-title":"Lancet Child Adolesc Health"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/523139-a-case-of-inadvertent-overdose-of-vosoritide-injection-in-a-three-month-old-infant-with-achondroplasia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:28:52Z","timestamp":1787016532000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/523139-a-case-of-inadvertent-overdose-of-vosoritide-injection-in-a-three-month-old-infant-with-achondroplasia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":6,"URL":"https:\/\/doi.org\/10.7759\/cureus.114690","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,17]]}}}